Press Releases

To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.

Non Regulatory

Initiator Pharma to present at Nordic Women’s Health Hub 2025

Initiator Pharma A/S, a clinical-stage biotech company, today announces that its CEO, Claus Elsborg Olesen, will present and together with Julia Persson, Founder of HappyLongevity and AI-Augmented Venture Designer, co-lead a session focused on health innovation at the upcoming Nordic Women’s Health Hub, taking place on September 8, 2025, 10.00–17.00 at Fællessalen, Christiansborg, Copenhagen, Denmark.

Read more
Non Regulatory

Initiator Pharma applies to initiate Phase 2a study in vulvodynia

Initiator Pharma A/S, a clinical-stage biotech company, has submitted a clinical trial application (CTA) to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), and local ethics committee in the UK for the approval to conduct a Phase 2a clinical proof-of-concept study in women suffering from vulvodynia, a severe chronic pain condition affecting approximately 10 percent of women worldwide. The study will be conducted together with MAC Clinical Research in the UK.

Read more
Regulatory

Initiator Pharma carries out a directed new share issue to guarantors

Initiator Pharma A/S (“Initiator” or the “Company”) has completed the rights issue of shares that was decided by the Board of Directors on May 19, 2025 (the “Rights Issue”). The Board of Directors of the Company has today, with the support of the authorization from the Extraordinary General Meeting in June 5 2025, resolved on a directed issue of shares to the guarantors in the Rights Issue who will receive their guarantee compensation in the form of shares in the Company (the “Compensation Issue”). The subscription price in the Compensation Issue is set at SEK 4.0 per share (corresponding to the subscription price in the Rights Issue) and payment is made by offsetting the guarantors’ claims on the Company regarding guarantee compensation.

Read more
Regulatory

Initiator Pharma announces outcome of rights issue

Initiator Pharma A/S (“Initiator” or the “Company”) announces the outcome of the Company’s rights issue of up to 14,039,590 shares (the “Rights Issue”), for which the subscription period ended on 26 June 2025. In the Rights Issue, 6 133 159 shares, corresponding to around 43.7 percent of the Rights Issue were subscribed through subscription rights. Additionally, 277 458 shares, corresponding to around 2.0 percent of the Rights Issue were subscribed without subscription rights. 5 670 164 shares, corresponding to around 40,4 percent of the Rights Issue were subscribed through guarantee undertakings. The Rights Issue will provide the Company with proceeds of approximately SEK 48.3 million before deduction of costs related to the Rights Issue.

Read more